NCT02775461Recruiting
Pancreas Registry and High Risk Registry
Pancreas Disease and High Risk Registry
Source: ClinicalTrials.gov · Last updated 11 Feb 2026
Brief summary (registry, in English)
The purpose of this study is to establish a registry of patients with pancreatic diseases. Patients included in the registry may include those with: pancreatic cancer, precancerous lesions of the pancreas, inflammatory lesions of the pancreas, cystic lesions of the pancreas, and patients at high-risk of pancreatic cancer such as those with a family history of pancreatic cancer or with a family history of a syndrome known to be associated with pancreatic cancer. Pancreatic cancer is the fourth leading cause of death from cancer in the United States. However, little is known about the development of pancreatic cancer and pancreatic diseases in individuals with the above conditions. Knowledge of how family history, environmental exposures, and inflammatory lesion of the pancreas contribute to the development of pancreatic cancer and pancreatic diseases is essential. You may qualify to take part in this research study because you have inflammation in the pancreas, a pancreatic cyst, pre-cancerous lesions of the pancreas, pancreatic cancer, a family history of pancreatic cancer, or a family history of a syndrome known to be associated with pancreatic cancer. We will also be collecting a blood sample from all participants for DNA isolation. Sometimes we are born with genes or DNA that give us an increased or decreased chance of developing an illness later in life. Genetic material will be isolated from your blood for further study. You may also choose to provide additional blood samples for serum and plasma extraction. Serum and plasma are components of the blood which can be used to measure indicators of disease in the blood, called biomarkers,for pancreatic diseases. Clinical data and biological specimens contained in this study may be used for a wide variety of future related studies to the cause, diagnosis, outcome and treatment of pancreatic cancer. Funds for conducting this research are provided by Mount Sinai.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1368 (estimated)
- First submitted
- 13 May 2016
- Start date
- 1 Mar 2013
- Primary completion date
- 31 Jan 2033
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Diseases
- Pancreatic cancer
- NCT number
- NCT02775461
What you commit to
- Study type: Observational
- Planned participants: 1368
- From 1 Mar 2013 to the primary completion date, 31 Jan 2033
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- Individuals under the age of 18 years
Other
- Patients who do not speak English or Spanish
- Refusal by patient
Who the study is looking for
- At least 1 first degree relative affected with Pancreatic Cancer
- Any of (BRCA1, BRCA2, PALB2, ATM) mutations + 1 family member with Pancreatic Cancer
- mFAMMM (p16,CDKN2A mutations) + 1 family member with Pancreatic cancer
- Known mutation carrier for STK11 (Peutz Jeghers Syndrome)
- Lynch syndrome (HNPCC) + 1 family PDAC
- Known mutation carrier for Hereditary pancreatitis
- Individuals with a history of pancreatic cyst(s) (IPMN's) that measure ≥ 1 cm
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mount Sinai West Coordinator of this site? Confirm its status | New York | United States | Recruiting |
| Icahn School of Medicine at Mount Sinai Coordinator of this site? Confirm its status | New York | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.